TSASPERA

Total Synthesis of (+)-Aspercyclide A and Analogues

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Brooke Cognome: Alasya Email: send email Telefono: +44 207 594 1181 Fax: +44 207 594 1418
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	180˙103 €
EC contributo	180˙103 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IEF
Funding Scheme	MC-IEF
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-03-13   -   2013-03-12

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Brooke Cognome: Alasya Email: send email Telefono: +44 207 594 1181 Fax: +44 207 594 1418	UK (LONDON)	coordinator	180˙103.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The incidence of allergic disease, from hay fever to asthma and anaphylactic shock, is increasing world-wide, nowhere more than in the UK where it has risen three-fold in 20 years and is now the highest in the world. Allergies including asthma afflict 40% of the UK population and bronchial asthma currently affects 5.2 million. The yearly cost to the UK National Health System in primary care alone exceeds €1,200M, and the loss of 18 million working days costs a further €1,400M. The quality of life for many sufferers is severely impaired. Historical medications (e.g. steroids) simply alleviate the side effects of allergy and are associated with debilitating side-effects. Recently, the humanised monoclonal antibody Zolair® has been approved for treatment of chronic asthma; this acts by inhibiting a specific protein-protein interaction (PPI) common to all allergic responses and is very effective but it is highly expensive and is administered via injection in a regime that is unsustainable for many body sizes. This research is aimed at the development of new a series of small, drug-like molecules based on a natural product lead as potential anti-asthma therapeutic leads with the same mode of action as Zolair®. The molecules will be prepared by synthesis and tested for activity in Enzyme-Linked Immunosorbent Assay (ELISA) and Surface Plasmon Resonance (SPR) assays and promising candidates subjected to co-crystallisation studies with their protein partner.'